In a nutshell This study examined the safety of combining carfilzomib (Kyprolis), cyclophosphamide (Cytoxan), and dexamethasone Decadron) for multiple myeloma. Researchers reported early results on the safety and potential effectiveness of this treatment combination. Some background Advances in first-line treatments have improved response and...
Read MoreMultiple Myeloma Posts on Medivizor
Adding pomalidomide to bortezomib and dexamethasone for multiple myeloma
In a nutshell This study examined the effects of pomalidomide (Pomalyst) in combination with bortezomib (Velcade) and dexamethasone (Decadron) in patients with relapsed or refractory multiple myeloma. This treatment combination was considered safe and effective for previously treated multiple myeloma. Some background Standard treatment for...
Read MoreLeukemia, CAR T-cell Therapy and Dr. Larry
Marathons are grueling 26.2 mile treks. The Boston Marathon is the oldest (started in 1897) and is one of the Marathon Majors (along with London, New York, Tokyo, Berlin and Chicago). Marathon Man Raising Money For LLS In 2001, at age 48, family practitioner, Larry Saltzman ran his first marathon in Chicago. That started a 13 marathon odyssey to...
Read MoreAdding daratumumab to bortezomib and dexamethasone for multiple myeloma
In a nutshell This paper studied the effects of daratumumab in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Daratumumab in combination with bortezomib and dexamethasone led to a longer survival period without worsening disease. Some background Multiple myeloma is a cancer of...
Read MorePomalidomide is safe and effective for advanced multiple myeloma when combined with dexamethasone
In a nutshell This study examined the safety and effectiveness of pomalidomide (Pomalyst) for multiple myeloma patients who have received multiple prior therapies. Researchers reported improved treatment outcomes when pomalidomide was combined with the steroid drug dexamethasone (Decadron) compared to pomalidomide alone. Some background Standard...
Read MoreDonor stem cells not recommended as part of tandem stem cell transplantation
In a nutshell This study analyzed the results of 5 trials to compare tandem stem cell transplant combinations for newly diagnosed multiple myeloma. Researchers do not recommend a double stem cell transplant, where the stem cells for the first transplant are sourced from the patient and in the second are sourced from a donor. Some background...
Read MoreEarly results of treatment with carfilzomib, pomalidomide, and dexamethazone for previously treated multiple myeloma
In a nutshell This study examined the safety of combining a biologic therapy (pomalidomide [Pomalyst]), a targeted therapy (carfilzomib [Kyprolis]), and a steroid drug (dexamethasone [Decadron]) for relapsed or refractory multiple myeloma. Researchers reported early results on the safety and potential effectiveness of this treatment combination. Some...
Read MoreRecording symptom burden and palliative care concerns in multiple myeloma patients
In a nutshell This study assessed symptom severity, quality of life and palliative care (treatment to relieve symptoms) concerns in multiple myeloma patients. Authors concluded that patients with multiple myeloma generally have a high symptom burden and low quality of life. Some background Multiple myeloma is the second most common type of blood...
Read MoreMultiple myeloma in older patients: Comparing treatment outcomes between fit and frail patients
In a nutshell This study analyzed the results of 3 trials to examine treatment outcomes in frail older patients with multiple myeloma. Authors reported poorer treatment outcomes and a higher rate of side effects among elderly patients in poorer health. Some background Over 60% of multiple myeloma cases are diagnosed in individuals aged above 65...
Read MoreRecommendations for the management, treatment and care of myeloma patients not able to undergo stem cell transplantation
In a nutshell This study reviewed the recommendations for the treatment and management of patients with multiple myeloma who are not able to undergo stem cell transplantation. Some background Multiple myeloma most frequently affects older patients. The standard treatment option is high-dose chemotherapy followed by stem cell transplantation (SCT)....
Read MoreIs carfilzomib effective with lenalidomide and dexamethasone in relapsed multiple myeloma?
In a nutshell This study compared the effectiveness of carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (Ozurdex) to lenalidomide and dexamethasone alone in patients with relapsed multiple myeloma. This study concluded that the addition of carfilzomib improved outcomes. Some background Survival rates for multiple myeloma have...
Read MoreComparing first-line treatment combinations with and without maintenance therapy
In a nutshell This study compared first-line treatment options for multiple myeloma with and without maintenance therapy. Researchers reported superior treatment outcomes with high-dose melphalan (Alkeran) plus stem cell transplantation when compared to a combination of orally administered treatments. Additional maintenance therapy with lenalidomide...
Read More
